1. Home
  2. STXS vs NYXH Comparison

STXS vs NYXH Comparison

Compare STXS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stereotaxis Inc.

STXS

Stereotaxis Inc.

N/A

Current Price

$2.09

Market Cap

201.6M

Sector

Health Care

ML Signal

N/A

Logo Nyxoah SA

NYXH

Nyxoah SA

N/A

Current Price

$3.62

Market Cap

190.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STXS
NYXH
Founded
1990
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.6M
190.6M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
STXS
NYXH
Price
$2.09
$3.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$4.00
$11.67
AVG Volume (30 Days)
405.1K
55.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,346,617.00
N/A
Revenue This Year
$24.21
$97.32
Revenue Next Year
$29.83
$241.74
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.54
$3.65
52 Week High
$3.59
$11.87

Technical Indicators

Market Signals
Indicator
STXS
NYXH
Relative Strength Index (RSI) 43.50 33.29
Support Level $2.06 N/A
Resistance Level $2.49 $5.02
Average True Range (ATR) 0.12 0.29
MACD 0.01 -0.08
Stochastic Oscillator 28.77 11.93

Price Performance

Historical Comparison
STXS
NYXH

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: